The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
The peptide increases the production of new neurons in the dentate gyrus, a phenomenon once thought impossible in adult brains but now recognized as ongoing throughout life at varying rates
Choose TB-500 if : Serious muscle or tendon injury Want most effective healing peptide Budget allows $120-200/month Comfortable with injection Need faster recovery than BPC-157 Use our TB-500 dosage calculator for protocols
GHK-Cu stimulates the production of collagen types I, II, and III, as well as elastin and the glycosaminoglycans that give skin its volume and hydration
Patients should also ask what evidence exists for their specific problem
